Last updated: February 15, 2026
Overview
NDC 76282-0680 is a biosimilar product equivalent to reference biologics. It targets indications such as rheumatoid arthritis and other autoimmune disorders. The product's market environment includes competition with originator biologics and other biosimilars, regulatory considerations, and pricing dynamics that influence its commercial potential.
Regulatory Status and Approvals
- The drug received FDA approval in [year].
- It is approved for multiple indications, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
- Regulatory pathways utilized include the 351(k) biosimilar pathway, facilitating approval based on analytical, preclinical, and clinical comparability.
Market Dynamics
- The biosimilar segment has gained momentum, driven by cost-saving policies and patent expirations for originator biologics.
- The industry sees increasing acceptance among providers and payers, with biosimilar penetration reaching approximately 30% in the biologic market by 2022 (source: IQVIA).
- Key competitors include other biosimilars and the innovator drugs, with market share distributions shifting in favor of biosimilars.
| Parameter |
Data Point |
| Market size (2019) |
$15 billion globally for biologics in autoimmune indications |
| Biosimilar market share (2022) |
30% of biologic prescriptions in the US |
| Price gap (biosimilar vs. originator) |
15-30% lower for biosimilars |
| Importantly, the list price of NDC 76282-0680 is estimated at $X per vial, reflecting average biosimilar pricing in the US, which tends to be approximately 20% lower than originator reference products (based on recent CMS and commercial payer data). |
Price Projection Models
Pricing projections depend on market uptake, payer policies, and competitive actions:
- Baseline Scenario: Market penetration reaches 50% of eligible patients within the first three years post-launch.
- Pricing trajectory:
- Year 1: List price stabilizes at current levels ($X per vial)
- Year 2-3: Price decreases by 10-15% due to increased competition
- Year 4-5: Further declines of 10%, driven by biosimilar market saturation and negotiated discounts
Projected average selling price (ASP):
| Year |
Estimated ASP per vial |
Notes |
| Year 1 |
$X |
Initial launch price |
| Year 2 |
$X - 10% |
Competitive pressure increases |
| Year 3 |
$X - 15% |
Greater market penetration |
| Year 4 |
$X - 20% |
Biosimilar options expand, further price reductions |
| Year 5 |
$X - 25% or more |
Mature market with predominant biosimilar utilization |
Revenue Projections
Assuming a patient population of approximately 100,000 eligible U.S. patients annually and full reimbursement, with conservative uptake assumptions:
| Year |
Patients On Drug |
Annual Revenue (USD millions) |
Market Share |
Comments |
| Year 1 |
10,000 |
$X |
10% |
Launch phase, early adoption |
| Year 3 |
50,000 |
$X |
50% |
Accelerated uptake, increased trust |
| Year 5 |
70,000 |
$X |
70% |
Market dominant biosimilar presence |
Pricing Sensitivity and Risks
- Payer negotiations: Discounts negotiated by payers can reduce realized prices by 15-25%.
- Regulatory and policy risks: Patent litigations, FDA formulary decisions, and CDE (Cost-Effectiveness) evaluations can influence pricing strategies.
- Market competition: The entrance of other biosimilars or innovator biologics with improved formulations could dampen price growth potential.
Key Takeaways
- NDC 76282-0680 is positioned in a matured biosimilar market with declining prices driven by competition.
- Pricing likely to stabilize around 20% below originator biologics initially, with further declines over five years.
- Revenue depends heavily on market penetration, payer acceptance, and regulatory developments.
FAQs
-
How does biosimilar pricing compare to originator biologics?
- Biosimilars are typically priced 15-30% lower than their reference products.
-
What factors influence biosimilar market adoption?
- Payer policies, provider acceptance, patient access programs, and regulatory landscape.
-
What is the expected lifespan of premium pricing?
- Premium pricing is unlikely beyond the first year; subsequent years see decreasing prices due to increased competition.
-
How do patent litigations impact biosimilar entry?
- Patent disputes can delay market entry, influencing initial pricing and market share.
-
Are there geographic differences in biosimilar pricing?
- Yes, European markets generally see lower biosimilar prices compared to the U.S. due to different regulatory and reimbursement systems.
References
[1] IQVIA, "Biologic and Biosimilar Market Report 2022."
[2] Centers for Medicare & Medicaid Services, "Pricing Data and Payer Trends."
[3] FDA, "Biologic Approvals & Biosimilar Guidelines," 2022.
